MD MBA - XORTX Therapeutics Chief Officer
| XRTX Stock | USD 1.21 0.02 1.68% |
Insider
MD MBA is Chief Officer of XORTX Therapeutics
| Age | 50 |
| Address | 3710 ? 33rd Street NW, Alberta Beach, AB, Canada, T2L 2M1 |
| Phone | 403 455 7727 |
| Web | https://www.xortx.com |
XORTX Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2936) %, meaning that it created substantial loss on money invested by shareholders. XORTX Therapeutics' management efficiency ratios could be used to measure how well XORTX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.57 in 2024. Return On Capital Employed is likely to rise to -0.88 in 2024. At this time, XORTX Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 189 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yael Barak | Neurosense Therapeutics | 54 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Alon BenNoon | Neurosense Therapeutics | 45 | |
| Tarek MD | Context Therapeutics | 63 | |
| Felix Kim | Context Therapeutics | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Elizabeth CPA | Context Therapeutics | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Niva RussekBlum | Neurosense Therapeutics | 45 | |
| Ferenc MD | Neurosense Therapeutics | 60 | |
| Evan Dick | Context Therapeutics | 72 | |
| Nedira SalzmanFrenkel | Neurosense Therapeutics | 36 | |
| Jennifer MinaiAzary | Context Therapeutics | 46 | |
| Linda Pestano | Ensysce Biosciences | 55 | |
| Diana Shtossel | Neurosense Therapeutics | 45 | |
| Sharon Vered | Neurosense Therapeutics | 58 | |
| Hagit Binder | Neurosense Therapeutics | 46 | |
| Or Eisenberg | Neurosense Therapeutics | 43 | |
| Geoffrey Birkett | Ensysce Biosciences | 61 | |
| Jeffrey Millard | Ensysce Biosciences | 48 | |
| Martin Lehr | Context Therapeutics | 40 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 |
XORTX Therapeutics Leadership Team
Elected by the shareholders, the XORTX Therapeutics' board of directors comprises two types of representatives: XORTX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XORTX. The board's role is to monitor XORTX Therapeutics' management team and ensure that shareholders' interests are well served. XORTX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XORTX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Charlotte May, Corporate Secretary | ||
| MRCP MD, Chief Officer | ||
| David MacDonald, Consultant Operations | ||
| Nick Rigopoulos, Director Communications | ||
| David MBA, Director Development | ||
| Allen Davidoff, CEO, Founder |
XORTX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XORTX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 2.64 K | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.80 X | ||||
| EBITDA | (4.87 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.